Antisense inhibition of striatal GABA(A) receptor proteins decreases GABA-stimulated chloride uptake and increases cocaine sensitivity in rats

Molecular Brain Research

Volumn 57, Issue 2, 1998, Pages 310-320

  Peris, Joanna ^a   Jung, Bruce J ^a   Resnick, Adam ^a   Walker, Paul ^a   Malakhova, Olga ^a   Bokrand, Yvonne ^a   Wielbo, Donna ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Antisense oligodeoxynucleotide; Cocaine; GABA receptor; Locomotion; Stereotypy

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; BRAIN RECEPTOR; CHLORIDE ION; COCAINE; FLUORESCEIN; MESSENGER RNA; RECEPTOR SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CHLORIDE TRANSPORT; CONTROLLED STUDY; DRUG SENSITIVITY; GABAERGIC TRANSMISSION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; ISOTOPE LABELING; LATERAL BRAIN VENTRICLE; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANALYSIS OF VARIANCE; ANIMALS; CHLORIDES; COCAINE; CORPUS STRIATUM; DOPAMINE UPTAKE INHIBITORS; GAMMA-AMINOBUTYRIC ACID; HALF-LIFE; MALE; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; STIMULATION, CHEMICAL; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0032526040     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(98)00102-8     Document Type: Article

References (55)

1. Ahktar S., Kole R., Juliano R.L. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 49:1991;1793-1801.
2. Beaucage S.L., Caruthers M.H. Deoxynucleoside phosphoramidite: a new class of key intermediates for deoxypolynucleotide synthesis. Tetrahedron Lett. 22:1981;1859-1864.
3. Borden L.A., Farb D.H. Mechanism of γ-aminobutyric acid/benzodiazepine receptor turnover in neuronal cells: evidence for non-lysosomal degradation. Mol. Pharmacol. 34:1988;354-362.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Branch A.D. A good antisense is hard to find. Trends Biochem. Sci. 23:1998;45-50.
6. Chiasson B.J., Armstrong J.N., Hooper M.L., Murphy P.R., Robertson H.A. The application of antisense oligonucleotide technology to the brain. Cell. Mol. Neurobiol. 14:1994;507-521.
7. A-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 359:1995;154-194.
8. Gale K., Marshall D., Bernstein H., Butler J. Effects of chronic cocaine administration on nigrostriatal function: neurochemical and behavioral changes in rats. Fed. Proc. 40:1981;291.
9. 1 mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49:1993;167-174.
10. Helene C., Toulme J.J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta. 1049:1990;99-125.
11. 3 subunit have epilepsy, cleft palate and hypersensitive behavior. PNAS. 94:1997;4143-4148.
12. Hooper M.L., Chiasson B.J., Robertson H.A. Infusion into the brain of an antisense oligonucleotide to the immediate early gene c-fos suppresses production of Fos and produces a behavioral effect. Neuroscience. 63:1994;917-924.
13. Jung B.J., Sealey S.A., Walker P.A., Peris J. Endogenous GABA release from striatal slices of cocaine sensitized rats. Soc. Neurosci. Abstr. 22:1996;929.
14. 2 subunit. Eur. J. Pharmacol. 291:1995;439-441.
15. 2 subunit induces loss of neurones in rat hippocampus. Neurosci. Lett. 202:1995;97-100.
16. Karle J., Witt M.R., Nielsen M. The use of in vivo antisense oligonucleotide technology for the investigation of brain GABA receptors. Neurochem. Int. 31:1997;437-446.
17. Karler R., Calder L.D., Thai L.H., Bedingfield J.B. The dopaminergic, glutamatergic, and GABAergic bases for the action of amphetamine and cocaine. Brain Res. 671:1995;100-104.
18. A receptors. J. Neurochem. 56:1991;1717-1722.
19. Kikuchi de Beltran K., Koshikawa N., Miwa Y., Kobayashi M., Stephenson J.D. Further evidence for a functional dorsal-ventral division of the rat striatum: GABAergic involvement in oral movements. Eur. J. Pharmacol. 239:1993;47-54.
20. Kole R., Shukla R., Ahktar S. Pre-mRNA splicing as a target for antisense oligonucleotides. Adv. Drug Deliv. Rev. 6:1991;271-286.
21. A receptor subunit mRNAs in the rat brain: II. Olfactory bulb and cerebellum. J. Neurosci. 12:1992;1063-1076.
22. Lloyd K.G., Pichat P., Scatton B., Zivkovic B., Morselli P.L., Bartholini G. The psychopharmacology of GABA synapses: update 1989. J. Neural. Transm. 29:1990;S13-S28.
23. Loke S.L., Stein C.A., Zhang X.H., Mori K., Nakanishi M., Subasinghe C., Cohen J.S., Neckers L. Characterization of oligonucleotide transport into living cells. PNAS. 86:1989;3474-3478.
24. A receptor decreases mouse brain benzodiazepine binding. Alcohol. Clin. Exp. Res. 18:1994;446.
25. McKenzie J.S., Shafton A.D., Stewart C.A. Intrastriatal dopaminergic agents, muscarinic stimulation, and GABA antagonism compared for rotation responses in rats. Behav. Brain Res. 45:1991;163-170.
26. 14C -plastic standards for quantitative autoradiography using LKB ultrafilm or Amersham hyperfilm Neurosci. Lett. 121:1991;211-214.
27. A receptor determined by electron microscopy image analysis. J. Neurochem. 62:1994;815-818.
28. A receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding in the rat CNS. J. Chem. Neuroanat. 3:1990;59-76.
29. G. Paxinos, C. Watson (Eds.), The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1986.
30. Pecins-Thompson M., Peris J. Behavioral and neurochemical changes caused by repeated ethanol and cocaine administration. Psychopharmacology. 110:1993;443-450.
31. A receptor-mediated chloride uptake is atypical in nigrocollicular areas. Life Sci. 53:1993;707-716.
32. A receptors. J. Pharmacol. Exp. Ther. 276:1996;1002-1008.
33. Peris J., Boyson S.J., Cass W.A., Curella P., Dwoskin L.P., Larson G., Linn L.-H., Yasuda R.P., Zahniser N.R. Persistence of neurochemical changes in dopamine systems after repeated cocaine administration. J. Pharmacol. Exp. Ther. 253:1990;38-44.
34. 35S -TBPS binding by bicuculline is region specific in rat brain Life Sci. 49:1991;PL49-PL54.
35. Peris J., Coleman-Hardee M.L., Burry J., Pecins-Thompson M. Selective changes in GABAergic transmission in substantia nigra and superior colliculus caused by ethanol and ethanol withdrawal. Alcohol. Clin. Exp. Res. 16:1992;311-319.
36. 3 subunit have increased behavioral sensitivity to cocaine. Soc. Neurosci. Abstr. 23:1997;2411.
37. A receptor research. Synapse. 21:1995;189-274.
38. A receptors modulate dopamine release from rat striatal synaptosomes. J. Neurochem. 61:1993;1634-1639.
39. Sommer W., Rimondini R., O'Connor W., Hansson A.C., Understedt U., Fuxe K. Intrastriatally injected c-fos antisense oligonucleotide interferes with striatonigral but not striatopallidal GABA transmission in the conscious rat. PNAS. 93:1996;14134-14139.
40. Stein C.A., Cohen J.S. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 48:1988;2659-2668.
41. Stein C.A., Mori K., Loke S.L., Subasinghe C., Shinozuka K., Cohen J.S., Neckers L. Phosphorothioate and normal oligodeoxyribonucleotides with S′ linked acridine: characterization and preliminary kinetics of cellular uptake. Gene. 72:1988;333-341.
42. Tidd D.M. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Anticancer Res. 10:1990;1169-1182.
43. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C.E., Reis D.J. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature. 363:1993;260-263.
44. Wahlestedt C., Pich E.M., Koob G.F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
45. Weiss B., Davidkova G., Zhang S.P. Antisense strategies in neurobiology. Neurochem. Int. 31:1997;321-348.
46. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Algers J.R., Neckers L.M. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. PNAS. 90:1993;4665-4669.
47. Wickstrom E.J. Oligodeoxynucleotide stability in subcellular extracts and culture media. Biochem. Biophys. Meth. 13:1986;97-102.
48. Wielbo D., Sernia C., Phillips M.I. The distribution and antihypertensive effects of phosphorothioated antisense oligodeoxynucleotides in SHR. Hypertension. 25:1995;314-319.
49. A receptor subunit mRNAs in the rat brain: I. Telencephalon, diencephalon, mesencephalon. J. Neurosci. 12:1992;1040-1062.
50. 1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res. 756:1997;76-83.
51. Yakubov L.A., Deeva E.A., Zarytova V.F., Ivanova E.M., Ryte A.S., Yurchenko L.V., Vlassov V.V. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors. PNAS. 86:1989;6454-6458.
52. A receptor β subunit heterogeneity: functional expression of cloned cDNAs. EMBO J. 8:1989;1665-1670.
53. A receptors containing one, two or three different subunits. Eur. J. Pharmacol. 301:1996;207-214.
54. 2 subunit increases convulsive threshold for β-CCM, a benzodiazepine inverse agonist, in rats. Eur. J. Pharmacol. 306:1996;61-66.
55. 2 dopamine receptors in mouse striatum. J. Pharmacol. Exp. Ther. 268:1994;1015-1023.